Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Churcher

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Current Topics in Medicinal Chemistry|May 23, 2006
Tau therapeutic strategies for the treatment of Alzheimer's diseaseIan Churcher
Journal of Medicinal Chemistry|November 17, 2017
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?Ian Churcher
Nature Chemistry|June 22, 2013
Reaction methodology: Speed dating for reactionsIan Churcher
Current Pharmaceutical Design|October 28, 2005
Gamma-secretase as a therapeutic target for the treatment of Alzheimer's diseaseIan Churcher, Dirk Beher
Current Opinion in Drug Discovery & Development|October 27, 2004
gamma-Secretase as a target for drug intervention in Alzheimer's diseaseTimothy Harrison, Ian Churcher, Dirk Beher
Angewandte Chemie (International Ed. in English)|January 25, 2012
Lead-oriented synthesis: a new opportunity for synthetic chemistryAlan Nadin, Channa Hattotuwagama, Ian Churcher
Nature Reviews. Chemistry|January 31, 2025
Return to FlatlandIan Churcher, Stuart Newbold, Christopher W Murray
Current Opinion in Drug Discovery & Development|September 9, 2009
Small-molecule modulation of cellular chaperones to treat protein misfolding disordersLisa A Sloan, Martin C Fillmore, Ian Churcher
Organic Letters|December 6, 2014
Asymmetric synthesis of trisubstituted aziridines via aza-Darzens reaction of chiral sulfiniminesToni Moragas, Ian Churcher, William Lewis, et al.
Drug Discovery Today|August 22, 2021
The rise and rise of protein degradation: Opportunities and challenges aheadScott J Hughes, Andrea Testa, Nicola Thompson, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Current Topics in Medicinal Chemistry|May 23, 2006
Tau therapeutic strategies for the treatment of Alzheimer's diseaseIan Churcher
Journal of Medicinal Chemistry|November 17, 2017
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?Ian Churcher
Nature Chemistry|June 22, 2013
Reaction methodology: Speed dating for reactionsIan Churcher
Current Pharmaceutical Design|October 28, 2005
Gamma-secretase as a therapeutic target for the treatment of Alzheimer's diseaseIan Churcher, Dirk Beher
Current Opinion in Drug Discovery & Development|October 27, 2004
gamma-Secretase as a target for drug intervention in Alzheimer's diseaseTimothy Harrison, Ian Churcher, Dirk Beher
Angewandte Chemie (International Ed. in English)|January 25, 2012
Lead-oriented synthesis: a new opportunity for synthetic chemistryAlan Nadin, Channa Hattotuwagama, Ian Churcher
Nature Reviews. Chemistry|January 31, 2025
Return to FlatlandIan Churcher, Stuart Newbold, Christopher W Murray
Current Opinion in Drug Discovery & Development|September 9, 2009
Small-molecule modulation of cellular chaperones to treat protein misfolding disordersLisa A Sloan, Martin C Fillmore, Ian Churcher
Organic Letters|December 6, 2014
Asymmetric synthesis of trisubstituted aziridines via aza-Darzens reaction of chiral sulfiniminesToni Moragas, Ian Churcher, William Lewis, et al.
Drug Discovery Today|August 22, 2021
The rise and rise of protein degradation: Opportunities and challenges aheadScott J Hughes, Andrea Testa, Nicola Thompson, et al.
Pageof 4